A Clinical and Molecular Phase II Trial of Oral ENMD-2076 in Ovarian Clear Cell Carcinoma (OCCC): A Study of the Princess Margaret Phase II Consortium.

Stephanie LheureuxAnna TinkerBlaise ClarkePrafull GhatageStephen WelchJohanne I WeberpalsNeesha C DhaniMarcus O ButlerKatia TonkinDavid Shao Peng TanKelly BrooksJanelle RamsahaiLisa WangNhu-An PhamPatricia A ShawMing S TsaoSwati GargTracy L StockleyAmit M Oza

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2018)

Single-agent ENMD-2076 did not meet the preset bar for efficacy. Loss of ARID1A correlated with better PFS on ENMD-2076 and warrants further investigation as a potential predictive biomarker.

Keyphrases

phase ii
open label
clinical trial
placebo controlled
phase iii
double blind
study protocol
human health
randomized controlled trial
climate change